Teniposide for advanced small cell lung cancer with c-Myc
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a chemotherapy drug called teniposide for people with a specific type of advanced small cell lung cancer that has gotten worse after prior treatment. The goal is to see if teniposide helps shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (cancer has spread beyond one lung).
- Your cancer has gotten worse after at least one round of chemotherapy.
- You are in good physical shape (ECOG score 0 or 1, meaning you can do daily activities or light work).
- Your cancer has a specific gene change called 'c-Myc-driven' (your doctor can confirm this).
- You are between 18 and 75 years old.
- You are able to give informed consent (understand and agree to be in the trial).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial compares two treatment approaches for people with relapsed extensive-stage small cell lung cancer. One approach uses a lab-grown tumor model (called an organoid) to pick a personalized drug, while the other uses a standard chemotherapy called topotecan.
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
This trial tests whether giving an immunotherapy drug called toripalimab together with chemotherapy after lung cancer surgery can help prevent small cell lung cancer from coming back. It is for people who had surgery to remove lung cancer and were found to have small cell lung cancer in the removed tissue.
This study tests whether a combination of three drugs—teniposide, cisplatin, and serplulimab—can effectively treat extensive-stage small cell lung cancer (a fast-growing type of lung cancer that has spread). Serplulimab is an immunotherapy drug designed to help your immune system fight cancer.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.